The dark side of clinical trials and remedial strategies in india

Raja Sekhar Reddy Poonuru; Keerthana Gabriela; Rohini Cheruku; Swetha Sreeramula; Prajwitha Mothukuri; Sneha  Bandari; Thanuj Reddy Bommineni; Akhila Madupu

doi:10.37022/jpmhs.v3i2.21

Authors

Raja Sekhar Reddy Poonuru Principal and Head, St.Peter’s Institute of Pharmaceutical Sciences, Hanamkonda, PIN – 506001, Telangana, India
Keerthana Gabriela Students, St.Peter’s Institute of Pharmaceutical Sciences, Hanamkonda, PIN – 506001, Telangana, India
Rohini Cheruku Students, St.Peter’s Institute of Pharmaceutical Sciences, Hanamkonda, PIN – 506001, Telangana, India
Swetha Sreeramula Students, St.Peter’s Institute of Pharmaceutical Sciences, Hanamkonda, PIN – 506001, Telangana, India
Prajwitha Mothukuri Students, St.Peter’s Institute of Pharmaceutical Sciences, Hanamkonda, PIN – 506001, Telangana, India
Sneha Bandari Students, St.Peter’s Institute of Pharmaceutical Sciences, Hanamkonda, PIN – 506001, Telangana, India
Thanuj Reddy Bommineni Students, St.Peter’s Institute of Pharmaceutical Sciences, Hanamkonda, PIN – 506001, Telangana, India
Akhila Madupu Students, St.Peter’s Institute of Pharmaceutical Sciences, Hanamkonda, PIN – 506001, Telangana, India

DOI:

https://doi.org/10.37022/jpmhs.v3i2.21

Keywords:

Clinical trial, Ethics, Informed consent, Schedule Y1

Abstract

India offers unique benefits to the clinical research fraternity of the world. Breadth of genetic variations, willing subjects due to poverty and abundant research talent brings the world to the door steps of our country. India needs to get its legal framework in to order to check the local exploitation and regulate unscrupulous foreign and domestic researchers. No law is effective unless it is implemented vigorously. Therefore strong executive institutions should be created to implement the laws with severe deterrent punishments. Pharmaceutical practitioners must take this to heart.

Downloads

Download data is not yet available.

References

Garner P, Kale R, Dickson R, Dans T, Salinas R. Implementing research findings in developing countries. BMJ. 1998; 317(7157):531-535.

Bhaswat S. Chakraborty. Clinical Research in India: The current scenario and prospects.J Adv Pharm Technol Res. 2013; 4(3): 126–127.

Marwah R, Van de Voorde K, Parchman J. Good clinical practice regulatory inspections: Lessons for Indian investigator sites. PerspectClin Res. 2010; 1:151–155.

Ernst&Young/FICCI, The Glorious Metamorphosis: Compelling Reasons for Doing Clinical Research in India, September 2009.

Bhatt A. Quality of clinical trials: A moving target. PerspectClin Res. 2011; 2:124–128.

CDSCO, Good Clinical Practices for Clinical Research in India, Schedule Y (Amended Version – 2005.

Sahoo U and Kumar N. The Regulatory Affairs Profession in India, The Regulatory Affairs Journal Pharma, 2007

Sinha K. 49 babies die during clinical trials at AIIMS. The Times of India. 2008 Aug 18 cited 2009 Jun 29.

Clinical Trials Transformation Initiative. Available from: http: / www.trialstransformation.org. [last Accessed on 2011 May 2].

Kleppinger CF, Ball LK. Building Quality in clinical trials with use ofa quality systems approach. Clin Infect Dis 2010; 51: S111-116.

Getz K. Protocol design trends and their effect on clinical trialperformance. Raj Pharma; 2008; 315-316.

Glickman SW, McHutchison JG, Peterson ED, Cairns CB, HarringtonRA, Califf RM, et al.. Ethical and scientific implications of theglobalization of clinical research. N Engl J Med 2009; 360:816-23.

Getz KA, Vogel JR. Successful outsourcing: Tracking global CROUsage. ApplClin Trials 2009; 18:42-50.

Meeker-O’Connell A. Enhancing clinical trial quality: CDERperspective Available from: http: / / www.fdanews.com / ext/ files / Conference / FIS10Presentations / MeekerOConnellHarmonizingRegulatoryApproaches.pdf. [Last accessed on 2011May 2].

Redfearn S. Step-up in FDA audits has sites scrambling to be ready.Centerwatch Mon 2011; 18:1-21.

Salewski JP. FDA Expectations of Clinical Trials and Investigators.Available from: http: / / www.fda.gov / downloads / ScienceResearch/ SpecialTopics / CriticalPathInitiative / SpotlightonCPIProjects /UCM236735.ppt. [Last accessed 2011 Mar 1].

US FDA Information Sheet Guidance for IRBs, Clinical Investigators,and Sponsors FDA Inspections of Clinical Investigators. Availablefrom: http: / / www.fda.gov / downloads / RegulatoryInformation /Guidances / UCM126553.pdf. [Last accessed on 2011 Aug 08].

Lou A. Preparing for an FDA Medical Device Sponsor Inspection.Available from: http: / / www.fda.gov / downloads / Training /CDRHLearn / UCM176843.pdf. [Last accessed on 2011 Jul 28].

Korieth K. Spike in warning letters sends tremors through industry.Centerwatch Mon 2010; 17:1-9.

Lou A. Preparing for an FDA Institutional Review Board InspectionAvailable from: http: / / www.fda.gov / Training / CDRHLearn /ucm180891.htm.[Last accessed on 2011 Jul 28].

Matzat J. Educating and training CRAs for the field. Monitor 2011; 32-5.

Ajay S, Bhatt A. Knowledge and skills at the study site – requirementsfor clinical research professionals in India: A Survey. CR Focus2008; 19:36-39.

Loff B, Black J. Research ethics committees: What is theircontribution? Med J Aust 2004; 181:440-441.

Morrison BW, Cochran CJ, White JG, Harley J, Kleppinger CF, Liu Aet al. Monitoring the quality of conduct of clinical trials: A survey ofcurrent practices. ClinTrials 2011; 8:342-349.

Abrol, D, P. Prajapati and N. Singh. Globalization of the Indian Pharmaceutical Industry:Implications for Innovation. International Journal of Institutions and Economies, 2011;. 3:327-365.

BavdekarSB, GogtayNJ and Wagh S. Reporting Ethical Processes in Two IndianJournals. Indian J Med Sci. 2008; 62:134-140.

Bhatt, A. Clinical trials in India: Pangs of Globalization,’ Indian Journal of Pharmacology. 2004;36:207-208.

Jayaraman K.S. Outsourcing clinical trials to India rash and risky, critics warn. Nature Medicine. 2004; 10:440.

The Lancet. Strengthening clinical research in India’ (Editorial), 2007; 369:1233.

Nundy S and Gulhati CM. A new colonialism?—conducting clinical trials in India. The New England Journal of Medicine. 2005; 352: 1633-1636.

Sengupta A. Fatal trials: clinical trials are killing people.Indian Journal of Medical Ethics. 2009; 3; 118-119.

Shetty P. Vaccine trial's ethics criticized. Nature. 2011; 474: 427–428.

Joseph J. Entering the contract research industry in India. Contemporary Clinical Trials. 2008; 29 (3):311-313.

Bhan A. Clinical trial ethics in India: one step forward, two steps back. Journal of Pharmacology and Pharmacotherapeutics. 2012; 3: 95-97.35. Roberts SL. Have India's poor become human guinea pigs.November 2012, News Magazine, BBC.

Jayaraman KS. Indian regulations fail to monitor growing stem-cell use in clinics. Nature. 2005; 434: article 259.